Supplements for Longevity & Their Efficacy | Dr. Peter Attia

Summary

This Huberman Lab conversation has Andrew Huberman and Peter Attia evaluate intravenous NAD, NR, NMN, sirtuins, resveratrol, rapamycin, and related longevity claims. Its central conclusion is that NAD biology and age-related change do not establish that raising NAD extends human healthspan or lifespan; Mechanism-to-Outcome Evidence Hierarchy requires tissue-relevant outcomes, controlled human evidence, and ideally survival or meaningful healthspan results. The episode uses the Interventions Testing Program and failed resveratrol and NR lifespan results to strengthen NAD Therapy Evidence Boundary, while continuing to rank exercise, sleep, nutrition, and emotional health above speculative supplementation.

Key Claims

• NAD Therapy Evidence Boundary separates NAD’s essential metabolic and sirtuin-related roles from proof that intravenous NAD, oral NR, or oral or sublingual NMN improves human healthspan or lifespan.
• Age-related NAD decline varies by tissue, and one blood finding described rising NADH alongside falling NAD, making redox balance and mitochondrial function more specific hypotheses than a simple total-NAD deficiency story.
• Interventions Testing Program results are treated as a stronger longevity test than mechanism alone: the episode reports no lifespan or healthspan benefit from NR, while rapamycin, canagliflozin, acarbose, and 17-alpha estradiol produced positive results in mice.
• Resveratrol illustrates how a proposed sirtuin mechanism and an unusual high-fat-diet mouse result can attract broad claims that later lifespan testing does not support.
• Human NR and NMN studies discussed in the episode show null primary outcomes, subgroup-sensitive findings, or statistically significant but clinically small biomarker changes rather than demonstrated longevity benefit.
• Raising NAD in blood or liver does not establish a meaningful effect in skeletal muscle or another target tissue, and biomarker or biological-age movement does not automatically establish clinical benefit.
• A possible reduction in basal- and squamous-cell skin cancers is treated as a signal worth replication, not proof of general cancer prevention, melanoma prevention, or lifespan extension.
• Sustainable Health Optimization remains foundations-first: exercise, sleep, nutrition, emotional health, muscle, strength, and power are presented as more consequential than the NAD products discussed.

Key Quotes

“no” — both speakers’ final answer to whether people should focus on NAD supplementation or infusions to extend life.

Connections

• Huberman Lab, Andrew Huberman, and Peter Attia - show, host, and guest context.
• NAD Therapy Evidence Boundary - central distinction between biochemical plausibility, reported subjective effects, biomarkers, and established clinical efficacy.
• Mechanism-to-Outcome Evidence Hierarchy - method used to separate pathways, animal results, subgroups, tissue biomarkers, and meaningful human outcomes.
• Interventions Testing Program - rigorous mouse-longevity benchmark used to compare NR with interventions that extended lifespan.
• Exercise Pillars For Longevity - muscle, strength, power, and physiological-reserve branch prioritized over supplements.
• Sustainable Health Optimization and Self-Experimentation - foundations-first practice and the limits of personal supplement or infusion experience.

Contradictions

• The episode materially qualifies the favorable NAD patient and self-reports in Peptide & Hormone Therapies for Health, Performance & Longevity | Dr. Craig Koniver: those observations may generate hypotheses, but negative NR lifespan testing and weak human outcome evidence leave longevity efficacy unestablished.
• Huberman reports energy and hair or nail changes after NMN and difficult symptoms during NAD infusion, but these uncontrolled observations do not establish efficacy, mechanism, or general tolerability.
• The skin-cancer signal, tissue NAD declines, NR/NMN pharmacology, human subgroup findings, biological-age-test criticism, radiation estimates, supplement regimens, and personal medication use remain source-scoped public medical discussion rather than individualized advice.